Weight Loss Study for People With Type 2 Diabetes (T2D)
This study is ongoing, but not recruiting participants.
Sponsor:
Medical University of South Carolina
Collaborator:
Weight Watchers International
Information provided by (Responsible Party):
Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT01601574
First received: April 27, 2012
Last updated: May 20, 2013
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the Weight Watchers program modified for use by people with Type 2 diabetes results in more improvements in blood glucose control relative to a control group receiving standard diabetes counseling.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Overweight Obesity |
Behavioral: Weight Watchers modified program Other: Standard Care group |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects on Glycemic Control and Weight of a Modified Commercial Weight Control Program for People With Type 2 Diabetes |
Resource links provided by NLM:
Further study details as provided by Medical University of South Carolina:
Primary Outcome Measures:
- Change in HbA1c [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in weight
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in BMI
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in waist circumference
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in fasting blood glucose
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in HOMA
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in cardiovascular risk markers (lipid measures, blood pressure, C-Reactive Protein)
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in diabetes medications.
- Secondary Endpoints [ Time Frame: Baseline and 12 months ] [ Designated as safety issue: No ]Change in various mental health assessments
| Estimated Enrollment: | 560 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | May 2014 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Modified Weight Watchers program |
Behavioral: Weight Watchers modified program
Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
|
| Active Comparator: Standard Diabetes Counseling group |
Other: Standard Care group
One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participant reported diagnosis of Type II diabetes
- HbA1c between 7%‐11% (inclusive)
- Fasting blood glucose < 240. If a potential participant has a FBG above the inclusion criteria it is acceptable to re‐test this potential participant within one week of the original test.
- BMI 27‐50 kg/m2 (inclusive)
- Age range - 18 - 70 (inclusive)
- Clearance on medical exam by study physician including EKG
- No weight loss over the previous 3 months (5kg loss is acceptable with physician discretion)
- On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)
- All diabetes medications are permitted including insulin.
- Willing and able to commit to regular physical activity (e.g. walking) five days per week
- Willingness and ability to make all scheduled appointments required by study protocol
- Willingness to attend weekly Weight Watchers meetings in the community and to participate in Weight Watchers online program, if so randomized
- Willing to follow requirements of study protocol
- Willing and able to provide a valid email address for use in the study
- Must be able to communicate (oral and written) in English
- Under the care of a physician for diabetes and willing to give release to contact the MD and request MD's agreement for participant to participate -
Exclusion Criteria:
- Type 1 Diabetes
- Cardiovascular/Coronary Heart Disease [e.g., MI or CVA within last 6 months, TIA, clinically significant arrhythmias, uncontrolled hypertension (defined as blood pressure over 160/110); physician's discretion may be more conservative]
- Current severe depression or history of severe depression within the previous year, based on DSM‐IV‐TR criteria for Major Depressive Episode
- Taking prescription or OTC weight loss medications within last 4 weeks
- Currently taking other medications that affect weight (e.g., paroxetine, tricyclics, anti‐psychotics)
- Within the last 4 weeks, use of chromium supplements or any nutrition supplements or herbal products claimed to have a weight loss effect. Participants using other non‐excluded nutrition supplements or herbal products must agree to continue at their current level of use throughout the study.
- Participation in a weight control program within the past 3 months
- QTc interval >450 msec for males and QTc interval >470 msec for females
- PHQ‐9 total score > 15
- Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable
- History of a surgical procedure for weight loss at any time (e.g. gastroplasty, gastric by‐pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)
- History of major surgery within three months of enrollment
- Presence of implanted cardiac defibrillator
- Orthopedic limitations that would interfere with ability to engage in regular physical activity
- Gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea or active gallbladder disease
- Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected basal cell carcinoma of the skin may be enrolled if treatment was completed more than 6 months prior to enrollment.
- History, within the past five years, of clinically diagnosed eating disorders Confidential March 30, 2012 9 including anorexia nervosa or bulimia nervosa.
- Women who are pregnant, lactating , trying to become pregnant or unwilling to use an effective means of birth control
- Participation in another clinical trial within 30 days prior to enrollment.
- Currently consuming >14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to limit intake to less than 3 drinks per drinking day during study participation
- Current or past drug abuse
- Participation in trial by another member of household
Hypoglycemic Events:
a. Evidence of more than 1 severe hypoglycemic event in the past 12 months, unless the participant's treating physician provides written clearance for participation.
- Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial -
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01601574
Locations
| United States, Alabama | |
| Diabetes Research and Training Center, University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35294 | |
| United States, California | |
| Scripps Clinical Research | |
| La Jolla, California, United States, 92037 | |
| United States, Georgia | |
| CSRA Partners in Health | |
| Augusta, Georgia, United States, 30909-6599 | |
| United States, Illinois | |
| Northwestern University Feinberg School | |
| Chicago, Illinois, United States, 60611 | |
| United States, New York | |
| Obesity Research Center St. Luke's Roosevelt Hospital Center | |
| New York, New York, United States, 10025 | |
| Weill Medical College of Cornell University | |
| New York, New York, United States, 10065 | |
| United States, North Carolina | |
| Center for Nutrition and Preventive Medicine | |
| Charlotte, North Carolina, United States, 28277 | |
| Obesity Clinical Trials Program Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Ohio | |
| Your Diabetes Endocrine Nutrition Group Inc. | |
| Mentor, Ohio, United States, 44060 | |
| United States, Oregon | |
| Oregon Weight Loss Surgery, LLC | |
| Portland, Oregon, United States, 97210 | |
| United States, Pennsylvania | |
| The University of Pennsylvania Center for Weight and Eating Disorders | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, South Carolina | |
| Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
| United States, Texas | |
| Baylor Endocrine Center | |
| Dallas, Texas, United States, 75246-1906 | |
| Oakwell Clinical Research | |
| San Antonio, Texas, United States, 78218 | |
| United States, Virginia | |
| Washington Center for Weight Management & Research, Inc The Navy League Building | |
| Arlington, Virginia, United States, 22201 | |
Sponsors and Collaborators
Medical University of South Carolina
Weight Watchers International
Investigators
| Study Director: | Patrick M. O'Neil, PhD | MUSC |
More Information
Additional Information:
Baylor Health 
Baylor Research 
No publications provided
| Responsible Party: | Medical University of South Carolina |
| ClinicalTrials.gov Identifier: | NCT01601574 History of Changes |
| Other Study ID Numbers: | WW-MUSC-1201 |
| Study First Received: | April 27, 2012 |
| Last Updated: | May 20, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Medical University of South Carolina:
|
Type 2 diabetes HbA1c Overweight Obesity |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Obesity Overweight Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Overnutrition Nutrition Disorders Body Weight Signs and Symptoms |
ClinicalTrials.gov processed this record on June 13, 2013